Chapter from the book *Common Eye Infections*
Downloaded from: http://www.intechopen.com/books/common-eye-infections

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
1. Introduction

Rheumatic diseases are a group of illnesses characterized by the inflammation of the connective tissue, usually of autoimmunological origin. Although most of the symptoms of the rheumatic diseases concern primarily musculoskeletal system, in many of these disorders pathological changes take also place in various other organs. Changes in the organ of sight in the rheumatic diseases may result from the inflammatory process taking place in the course of immunological dysfunctions and their manifestations may precede typical in these illnesses musculoskeletal symptoms. Damage to the organ of sight may also be secondary to vascular lesions occurring in the course of its inflammation or may be the result of complications arising from the therapy of the rheumatic disease. (Table 1).
Systemic vasculitis Polyarteritis nodosa Churg-Strauss syndrome Wegener’s granulomatosis Behçet’s disease Takayasu’s disease Giant cell arteritis Cogan syndrome

Table 1. Rheumatic diseases with changes occurring in the organ of sight.

2. Characteristics of rheumatic diseases, in which the most frequent changes in the organ of sight occur

The rheumatoid arthritis (RA) and spondyloarthropathies (SpA) are the most common inflammatory rheumatic diseases. Significantly less frequently juvenile idiopathic arthritis (JIA), Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE) and other less frequent connective tissue diseases as scleroderma, dermato-and polymiositis, recurrent inflammation of the cartilage and systemic vasculitis are observed.

2.1. Rheumatoid arthritis

Rheumatoid arthritis is an autoimmune connective tissue disease that manifests itself mostly with symmetrical swelling of the joints (particularly of the hands) - and with morning stiffness. The incidence of RA in the world is estimated at about 0.33 -1.5% of the total population [1,2,3,4,5,6]. The diagnosis of RA is based on the current 2010 ACR / EULAR criteria. The diagnosis of RA is definite when the summary point record for all criteria (A + B + C + D) reaches ≥ 6 out of 10. (Table 2) [7].

<table>
<thead>
<tr>
<th>A. Joint involvement</th>
<th>1 large joint</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2-10 large joints</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1-3 small joints (with or without involvement of large 2 joints)</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4 - 10 small joints (with or without involvement of joints)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>*/ 10 joints (at least 1 small joint affected)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. serological tests (at least one required)</th>
<th>Negative results for the presence of RF and ACPA</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive results in the presence of low-titer RF and ACPA</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Positive results in the presence of high titer of RF and ACPA</td>
<td>3</td>
</tr>
</tbody>
</table>
Table 2. ACR/EULAR 2010 classification criteria for rheumatoid arthritis

<table>
<thead>
<tr>
<th>C. indicators of acute fase (at least one required)</th>
<th>Valid values for CRP and ESR</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incorrect values of CRP and ESR</td>
<td>1</td>
</tr>
<tr>
<td>D. duration of symptoms</td>
<td>&lt;6 weeks</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>≥ 6 weeks</td>
<td>1</td>
</tr>
</tbody>
</table>

RF – Rheumatoid Factor, ACPA – Anti-Citrullinated Protein Antibodies, CRP – C-Reactive Protein, ESR – Erythrocyte Sedimentation Rate

Approximately 40% of patients with RA present not only joint inflammation but also clinical symptoms resulting from other organ involvement [8].

Frequently, in as many as about 30% of patients with rheumatoid, rheumatoid nodules occur [9]. The changes in the lungs, such as pleural involvement, take place in approximately 50% of patients, but only in 10% of cases are identified [10]. Similarly frequently autopsy reveals changes in the heart.

In echocardiography pericardial effusion is revealed in 31% of patients [11]. 1 - 5% of patients with RA are diagnosed with vasculitis, while autopsy studies detect these changes in 15-31% of patients [12,13]. Changes in the eyes in the course of RA are observed in approximately 25% of patients [14, 15]. The treatment of RA is based on disease-modifying drugs (DMARDs) such as methotrexate, sulfasalazine, leflunomide, cyclosporine, cyclophosphamide, hydroxychloroquine or chloroquine and gold salts. Furthermore, patients often have glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs) administered orally or locally (intra-articularly). In the contemporary rheumatology in case of ineffectiveness of the traditional DMARDs therapy second line treatment is implemented - based on biological agents. These include TNF-alpha (tumor necrosis factor) inhibitors such as adalimumab, certolizumab pegol, etanercept, golimumab, infliximab as well as drugs with other mechanism of action such as abatacept (anti-CTL-4), rituximab (anti-CD 20) and tocilizumab (anti-IL-6) [16].

Figure 1. Scleromalacia perforans in patient with long-term RA (photo by D. Kopacz).
2.2. Spondyloarthropathies

Spondyloarthropathies (SpA) are a group of diseases characterized by similar clinical symptoms and genetic predispositions.

Table 3. ASAS classification criteria for axial spondyloarthropathy

<table>
<thead>
<tr>
<th>Back pain lasting ≥3 months with the start in &lt;45 years of age (with or without peripheral symptoms of the disease)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sacroilitis in imaging tests results + or + 1 symptom of spondyloarthropathy</td>
</tr>
<tr>
<td>Presence of HLA-B27 antigen + or + ≥2 symptoms of spondyloarthropathy</td>
</tr>
</tbody>
</table>

Symptoms of SpA:
- The pain of an inflamed sites
- Arthritis
- Enthesitis
- Iritis
- Dactylitis
- Psoriasis skin
- Leśniowski-Crohn’s disease / colitis ulcersa
- Good response to non-steroidal anti-inflammatory drugs
- A history of SpA in the family
- The presence of HLA-B27 antigen
- Increased levels of CRP

Table 3. ASAS classification criteria for axial spondyloarthropathy
Spondyloarthropathies can be divided into 2 groups according to the predominant symptoms. The domination of symptoms suggestive of spinal involvement, such as inflammatory back pain (IBP) - i.e. pain escalating at night, decreasing after exercise, not alleviated by the period of rest - defines axial spondyloarthropathy. In patients with prevalence to enthesitis and peripheral arthritis, the peripheral spondyloarthropathy is diagnosed. ASAS Group (Ankylosing spondylitis In Assessment) has developed diagnostic criteria common to these diseases (Table 3.4) [17, 18].

<table>
<thead>
<tr>
<th>Peripheral arthritis (most commonly of the lower extremities and/or asymmetrical) or enthesitis (enthesitis), or sausage fingers (dactylitis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AND</td>
</tr>
<tr>
<td>≥ 1 symptom of SpA ≥ 2 other symptoms SpA</td>
</tr>
<tr>
<td>- Psoriasis - arthritis</td>
</tr>
<tr>
<td>- Crohn's disease-Leśniowski / colitis ulcerosa or - inflammation of the tendon</td>
</tr>
<tr>
<td>- Prior to infection - dactilitis , sausage fingers</td>
</tr>
<tr>
<td>- presence of HLA-B27 antigen - inflammatory back pain (ever)</td>
</tr>
<tr>
<td>- Uveitis - a history of SpA in the family</td>
</tr>
<tr>
<td>- Inflammation of the sacroiliac joints in imaging tests (X-ray or MRI)</td>
</tr>
</tbody>
</table>

Table 4. ASAS classification criteria for peripheral spondyloarthropathy

There separate classification criteria for particular spondyloarthropathies such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis in course of ulcerative colitis and Leśniowski- Crohn's disease are also established.

Spondyloarthropathies incidence is similar to that of RA and ranges from 0.15 to 1.8% of the general population [19,20,21].

The uveitis affects approximately 0.5% of patients with spondyloarthropathies, and frequency of its occurrence varies depending on the type of spondyloarthropathies. In AS uveitis occurs in 0.8% of patients, while in about 2.3% of patients with the PsA [22]. Ocular changes in SpA related to non-specific inflammatory bowel disease (ulcerative colitis, Leśniowski Crohn's disease) occur in up to 4-12% of patients [23,24].

Conjunctivitis occurs in 33-100% of patients with reactive arthritis [25] and 20 to 33% of patients with PsA [26].

The treatment of spondyloarthropathies is based on non-steroidal anti-inflammatory drugs, disease-modifying drugs such as methotrexate, leflunomide, sulfasalazine, cyclosporyna and biological agents from the group of anti-TNF-alpha. The glucocorticoids are also used in intraarticular injections [27,28].
2.3. Juvenile idiopathic arthritis

Juvenile idiopathic arthritis is the most common form of chronic inflammation of the connective tissue in children. Prevalence in the population is 43-148 cases per 100,000 persons [29, 30, 31]. The diagnosis of JIA is based on the 1997 ILAR criteria. For the arthritis to be diagnosed as JIA, the onset of the disease must take place until 16 years of age, arthritis symptoms must last more than 6 weeks and other diseases in which arthritis occurs have to be excluded (e.g., infectious, reactive, toxic and allergic and neoplastic diseases and other conditions with joint involvement). Ocular complications - mainly uveitis - occur in approximately 12-17% of juvenile patients [32]. Treatment, as in RA, is based on DMARDs and biological agents.

2.4. Systemic lupus erythematosus (SLE)

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with diverse symptomatology resulting from involvement of many organs and systems. The prevalence of SLE in the general population ranges from 0.016 to 0.092% [33, 34, 35]. The typical clinical features of SLE include facial erythema, discoid rash, photosensitivity, oral ulcers, arthritis, pleurisy or pericarditis, kidney changes, changes in the central nervous system, haematological disorders (such as hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia), immune changes with presence of antinuclear, anti-DNA and anti-Śm autoantibodies, as well as false positive syphilis tests. SLE may be associated with antiphospholipid syndrome (APS) with thrombotic episodes in the arteries and veins and obstetrics failure in women. Diagnosis is based on the revised 1997 ACR classification criteria [36]. Changes in the organ of sight occur in approximately 25% of patients, mainly in the course of secondary Sjögren’s syndrome but also as result of vasculitis and thrombosis [37]. Conjunctivitis, episcleritis and interstitial keratitis are rare [38].

2.5. Primary Sjögren’s syndrome

Primary Sjögren’s syndrome (pSS) is an inflammatory autoimmune disease that occurs most often in women between 40 and 50 years of age. The clinical symptoms of the disease result from B cell autoreactivity, polyclonal immunoglobulin overproduction and infiltration of exocrine glands by lymphocytes (CD4 cells predominate). The dominant symptom is dryness of the mouth and eyes. The nonerosive arthritis, vasculitis, peripheral neuropathy and different symptoms from central nervous system are also observed in pSS. According to different data Sjögren’s syndrome prevalence rate ranges from 0.2 to 13.3% of the population [39, 40, 41]. Sjögren’s syndrome is diagnosed on the basis of the revised 2002 American-European criteria [42]. Ocular symptoms associated with impaired secretion of tears occur in all patients with Sjögren’s syndrome – either in the initial or more advanced stages of the dis-
ease – and constitute one of to the diagnostic criteria. Treatment is based on the use of both symptomatic drugs - moistening eyes and mouth – and of immunosuppressants.

2.6. Scleroderma

Scleroderma is an inflammatory connective tissue disease of unknown etiology characterized by the damage to blood vessels, the presence of autoantibodies (SCL 70 or anticentromeric autoantibodies for diffuse systemic sclerosis and localised systemic sclerosis respectively) and progressive fibrosis of the skin and internal organs. Systemic sclerosis prevalence rate in the world is ranging from 0.0007% to 0.265% [43,44,45]. Disease diagnosis based on the classification and diagnostic criteria of the 1980 ACR [46]. 71% of patients present changes in blood and conjunctival subepithelial fibrosis. In course of SS all structures of the eye may be affected [47,48]. Patient with SS may develop secondary Sjogren’s syndrome and symptoms of dry eye, as well as complications due to the dryness of the conjunctiva [49].

2.7. Recurrent inflammation of the cartilage

Recurrent inflammation of the cartilage is a rare inflammatory autoimmune disease in which the inflammatory process involving mostly cartilage, causing changes and dysfunction of many tissues and organs. Onset of the disease usually affects people of 40-60 years of age and the prevalence of this disease in the world is estimated at about 3 cases per 1 million people in the population [50]. Currently, the diagnosis of this disease can be based on the diagnostic criteria of McAdam, 1976 [51]. Changes in the organ of vision occur in approximately 60% of patients and may include almost all structures of the eye [52, 53].

2.8. Systemic vasculitis

In the course of systemic vasculitis such as polyarteritis nodosa, Churg-Strauss syndrome, Wegener’s granulomatosis, Behçet’s disease, Takayasu disease, giant cell arteritis and Cogan syndrome there are changes in the organ of sight secondary to vascular changes. In polyarteritis nodosa ocular changes are observed in approximately 10-20% of patients [54,55], in Wegener’s granuloma in 28-58% of patients [56,57] Behçet’s disease in 68-85% of patients [58, 59, 60]. The ocular changes in course of inflammation of the large vessels, such as giant cell arteritis, are mainly associated with ischemia of optic nerve or retina. Ischemia causes impairment of vision and blindness, which may occur in 13 to 70% of patients [61,62]. The treatment of all systemic vasculitis requires aggressive immunosuppressive therapy and high doses of glucocorticoids. In some cases of very active disease and no reaction to other treatment, especially in case of Wegener’s granuloma, biological therapy (rituximab) is used [63,64].
3. Characteristic changes in the organ of sight in rheumatic diseases

The pathological changes can occur in all elements of the organ of sight in the course of rheumatic diseases. These can cause temporary or permanent damage (Table 5). Changes in the eyes are the first symptom of rheumatic fever observed in approximately 4% of patients [65].

<table>
<thead>
<tr>
<th>type of symptoms and changes in the eye</th>
<th>rheumatic disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>conjunctivitis</td>
<td>Reactive arthritis</td>
</tr>
<tr>
<td></td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>dryness</td>
<td>Sjögren’s syndrome</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid vasculitis</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td>Systemic vasculitis</td>
</tr>
<tr>
<td>Uveitis:</td>
<td>Spondyloarthropathies</td>
</tr>
<tr>
<td>Acute anterior uveitis</td>
<td>Behçet disease</td>
</tr>
<tr>
<td>Chronic anterior uveitis</td>
<td>colitis ulcerosa/ Leśniowski - Crohn’s disease</td>
</tr>
<tr>
<td>Panuveitis</td>
<td>colitis ulcerosa/ Leśniowski-Crohn’s disease</td>
</tr>
<tr>
<td></td>
<td>relapsing polychondritis</td>
</tr>
<tr>
<td></td>
<td>Behçet disease</td>
</tr>
<tr>
<td>Scleritis</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td>systemic vasculitis</td>
</tr>
<tr>
<td></td>
<td>Colitis ulcerosa/ Leśniowski-Crohn’s disease</td>
</tr>
<tr>
<td></td>
<td>Relapsing polychondritis</td>
</tr>
<tr>
<td>Keratitis:</td>
<td>Sjögren’s syndrome</td>
</tr>
<tr>
<td>Non-necrotizing corneal melt</td>
<td>Rheumatoid vasculitis</td>
</tr>
<tr>
<td>Necrotizing keratitis</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td>systemic vasculitis</td>
</tr>
<tr>
<td>Retinal vasculopathy</td>
<td>Systemic Lupus erythematosus</td>
</tr>
<tr>
<td>Microvasculopathy</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>Diffuse vaso-occlusive disease</td>
<td>Antiphospholipid syndrome</td>
</tr>
<tr>
<td></td>
<td>Behçet disease</td>
</tr>
<tr>
<td>Optic nerve disease</td>
<td>Systemic vasculitis (particular giant cell vasculitis)</td>
</tr>
<tr>
<td>Ischemic optic neuropathy</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. The most common ocular changes in the course of the rheumatic diseases.

Changes in the eyes in course of the rheumatic diseases may also be caused by the implemented treatment. Nonsteroidal anti-inflammatory drugs are medications most commonly used in alleviating the symptoms of rheumatic diseases. Cases of keratopathy (keratopathy) after indomethacin use have been reported [66], and diplopia (double vision) and ambylophia (amblyopia) after ibuprofen and naproxen treatment [67]. Antimalaric drugs such as hydroxychloroquine and more often chloroquine may aggregate in the cornea [68], in 13 - 40% of patients causing retinopathy [69,70]. Gold salts - administered parenterally over the total
dose of 1000mg/kg of body weight – accumulate in various tissues of the body and have been observed in the eyes (conjunctiva, cornea, anterior lens and retina) in 97% of patients [71]. Gold salt deposits in the eyes may cause hypersensitivity reactions, induce inflammation and cause marginal ulceration [72]. After methotrexate therapy diffuse irritation of the cornea is observed [73]. Chronic glucocorticoid therapy often leads to cataracts, subcapsular cataracts and glaucoma [74, 75].

4. Infectious complications of the eyes in rheumatic diseases

Viral, bacterial and fungal infectious complications occur in the organ of sight in patients with rheumatic diseases more frequently than in healthy individuals due to the immunological system dysfunctions, immunosuppressive therapy and chronic use of corticosteroids.

4.1. Infective conjunctivitis

4.1.1. Bacterial conjunctivitis

Chlamydial conjunctivitis

Reactive arthritis, which belongs to spondyloarthropaties, may be caused by infection with Chlamydia trachomatis and Chlamydia pneumoniae [76]. In the course of the infection with Chlamydia trachomatis (serotypes DK) chronic conjunctivitis occurs in 6-19% of patients [77, 78]. Chlamydial conjunctivitis most commonly affects sexually active adults, especially men. Chlamydia DNA is detected by PCR (polymerase chain reaction) in 96% of patients with reactive arthritis concomitant conjunctivitis, leakage from the urethra and inflammation of asymmetric arthritis (former name of these symptoms is Reiter’s syndrome) [79]. Eye involvement probably occurs by the way of self infection from the genitourinary system, or from one eye to another. In chlamydial conjunctivitis in adults symptoms initially occur in one of the eyes. It was also found that conjunctivitis may also occur (less frequently than in Chlamydia trachomatis) in the course of Chlamydia pneumoniae infection – as was demonstrated by confirming the presence of bacterial DNA from conjunctival scraping [80].

Clinical symptoms of chlamydial conjunctivitis in reactive arthritis are characterized by moderate redness of a single eye or less commonly of both eyes, tearing, photophobia and decreased vision. Ocular examination shows conjunctival hyperemia, chemosis and follicular reaction in conjunctiva and semilunar folds. Epithelial and subepithelial infiltrates in cornea may develop.

The histopathology assessment reveals the presence of the chronic inflammation cells localized in submucosal layer, with the predominance of lymphocytes. In addition, fibrinogen deposits in the basal membrane of conjunctiva, infiltration of lymphocytes and macrophages around small blood vessels and lymphocytic infiltration of the walls of larger vessels of conjunctiva have been observed [81].
Diagnosis is based on the detection of IgM, IgG and IgA antibodies to these bacteria in the blood serum by ELISA method and confirmation with W-blot test. Classical method is a detection of Chlamydia basophilic intracytoplasmic inclusions in primary cells from the conjunctival swab or conjunctival scraping using DFA (direct immunofluorescence staining) method, DNA hybridization tests or PCR (polymerase chain reaction and LCR (Ligase chain reaction).

Treatment of chlamydial conjunctivitis infection in the course of reactive arthritis consists of systemic antibiotic therapy and topical use of tetracycline, erythromycin or fluoroquinolones. In systemic treatment effectiveness of macrolides (azithromycin), tetracyclines and quinolones has been shown [82,83, 84]. Single dose of azithromycin (1000mg) showed efficacy in eradication of C. trachomatis infection [85]. It’s vital to stress that chlamydia infection is still the main cause of blindness on the African Continent. In the case of trachoma present drug of choice is azithromycin [86]. Because C. trachomatis infection is sexually transmitted, other similarly transmitted co-infections should be considered, most commonly gonococcal.

4.1.2. Fungal conjunctivitis

Significantly higher incidence of fungal conjunctivitis is observed in patients with rheumatic diseases treated with systemic glucocorticoids (eg, RA) and in patients with primary Sjögren’s syndrome. The most common pathogens are Candida albicans and Candida parapsilosis [87].

5. Infectious scleritis in rheumatic diseases

It has been shown that in patients with scleral inflammation lasting over 12 years, 7.5% of them had infectious complications, usually caused by herpes zoster virus [88]. Infectious complications can be even more frequent in patients with rheumatic diseases who are chronically treated with immunosuppressive drugs. The use of immunosuppressive drugs can cause reactivation of latent Mycobacterium tuberculosis infection which, in the form of nodular scleritis may occur in the eye [89]. There are reports of the occurrence of tuberculosis uveitis during treatment with etanercept (soluble anti TNF inhibitor) [90].

6. Infectious keratitis in rheumatic diseases

6.1. Viral keratitis

In RA patients inflammatory corneal ulceration may occur as a symptom of this disease. However, any such changes require the differentiation from herpes simplex infection, which presents the same clinical picture. The differentiation is important from the point of implemented treatment, because corneal ulceration in course of RA requires a very intensive immunosuppressive therapy, which exacerbates an inflammation caused by herpes simplex infection [91].
6.2. Bacterial keratitis

Bacterial keratitis in rheumatic diseases often is a complicated by erosive lesions of the cornea. Such changes are most commonly associated with primary and secondary Sjögren's syndrome. Most frequently - up to 73.9% - patients suffer from Gram-positive bacterial infections of as coagulase-negative Staphylococci, Staph. aureus and Streptococcus pneumoniae. 0.3% of patients suffer from infections of Gram-negative Moraxella spp. Infections with Gram-positive bacteria are present in 17.4% of patients; most common are: Propionibacterium acnes, Corynebacterium spp. 6.5% patients reveal infections caused by Pseudomonas aeruginosa and Proteus spp [92,93].

6.3. Fungal keratitis

The fungal infections of the cornea may also develop in the primary and secondary Sjogren's syndrome due to improper hydration of the eye – both because of the composition of tears and rupture in the tear film. In 45.8% of patients with fungal infection of the cornea Candida albicans is the major pathogen, while Fusarium spp accounts for approximately 25% of the infections.

7. Comment

In the light of the wide use of immunosuppressive therapy, in particular in the era of biological therapies in rheumatic diseases, close attention should be paid to the possible reactivation of latent infections. Most commonly tuberculous infection should be considered, but viruses like Cytomegalovirus (CMV) may also be present in patients in their persistent form. In similar circumstances - in AIDS patients and patients after organ transplantations (e.g. bone marrow transplantation) - CMV retinitis has been reported. Currently there are reports of CMV retinitis in the course of treatment RA with infliximab (anti TNF) [94].

Finally, it should be noted that biological drugs have proved effective in the treatment of ocular manifestations of many rheumatic diseases and the exclusion of potential infection is particularly important for the choice of treatment and safety of therapy.

Author details

Brygida Kwiatkowska and Maria Maślińska

*Address all correspondence to: maslinskam@gmail.com

Institute of Rheumatology, Poland
References


